Lumendi Ltd. develops, markets and distributes surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions.
The company was founded 2014 and holds the worldwide exclusive licence on the DiLumenTM technology. All devices were developed by Lumendi in collaboration with the Minimally Invasive New Technologies program (MINT) at Weill Cornell Medical College (Cornell University).
The device platform are disposable accessories for enhanced endoscopic interventions. It creates a Therapeutic Zone (TZ) in the large intestine and improves stability of the endoscope and visualization for removal of colonic lesions such as complex polyps. DiLumenTM was launched in the US in May 2017 and since then has built up a proven track record in reducing time of procedures and improving therapeutic outcomes.
Lumendi’s first product, DiLumenTM, is already commercially available in the USA and has demonstrated its advantages in performance and therapeutic benefits in over 300 procedures. CE Mark for the European market is expected in Q2/2018.
The second generation of the product, DiLumen C2 TM EIP, provides two additional working channels on the sheet and applies flexible articulating surgical instruments that expand the capabilities for complex GI interventions. It has the potential to replace open surgical or laparoscopic procedures with incision-free endolumenal procedures, which represents clear advantages for patient care and cost savings. The development of Lumendi’s innovative products is supported by leading endoscopists and GI surgeons on the company’s Clinical Advisory Board. Lumendi Ltd. is currently pursuing market expansion and is evaluating the best partners to market the products in Europe and the Asia/Pacific region.
For more information how you can participate on Lumendi’s opportunities for growth, please call +44 20 3369 8694 or email InvestorRelations@lumendi.com